GLP-1 Medications for Weight Loss: How to Get Started
Approval (2017) FDA Approves Treatment For Chronic Weight Management in Pediatric Patients Aged 12 Years and Older (June 27, 2022)
A phase 2 trial assessing different doses of bimagrumab (up to 30 mg/kg) in combination with semaglutide as obesity treatment is ongoing (NCT05616013)
Lilly now has injectable retatrutide for the highest-efficacy patients, injectable tirzepatide for the broad obesity population, and oral orforglipron for patients who refuse injections
To minimize side effects, we: Use a gradual dosing schedule Provide guidance on hydration and nutrition Recommend smaller, more balanced meals Monitor your progress closely Support is ongoing, and adjustments are made as needed to keep the process as comfortable as possible
They spend adequate time in bed but wake up feeling unrested